Open AccessPreferential Hyperacuity Home Testing for Monitoring Intermediate Age-related Macular Degeneration in Routine Clinical Practice
Author(s) -
Yue Zhao,
Grant L Hom,
Thais F. Conti,
Sumit Sharma,
Alex Yuan,
Aleksandra Rachitskaya,
Sunil K. Srivastava,
Peter Kaiser,
Rishi P. Singh
Publication year - 2020
Publication title -
american journal of ophthalmic clinical trials
Language(s) - English
Resource type - Journals
eISSN - 2576-1013
pISSN - 2576-1005
DOI - 10.25259/ajoct_3_2020
Subject(s) - macular degeneration , medicine , choroidal neovascularization , visual acuity , hyperacuity , optometry , ophthalmology , artificial intelligence , computer science
Objectives: A home monitoring device (ForeseeHome; Notal Vision, Tel Aviv, Israel) detected choroidal neovascularization in age-related macular degeneration (AMD) earlier than home and office monitoring. This study describes device usage in routine clinical practice. Materials and Methods: An Institutional Review Board-approved retrospective chart review of intermediate AMD patients who used the device at a single tertiary care center. Primary outcomes were duration and frequency of usage and outcomes of alerts generated. Results: Sixty-two patients (106 eyes) completed monitoring 4.2 ± 2.1 times per week (avg ± std dev) from February 2015 to February 2019. Forty-five eyes discontinued monitoring after an average of 65 days (range 13–237 days), due to poor quality tests (62%), and false-positive alerts (16%). Eyes that discontinued device monitoring were older and had poorer visual acuity than eyes that continued monitoring ( P < 0.01). Fourteen alerts were generated, of which one represented conversion to exudative AMD. Two additional converted eyes were identified by routine office visit and Amsler grid monitoring. Conclusions: Home monitoring has the potential to improve the detection of exudative AMD. Identifying barriers to device utilization are necessary in the AMD population.